{"id":"fluticasone-salmeterol-diskus-250-50","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL1473","moleculeType":"Small molecule","molecularWeight":"500.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone is a potent glucocorticoid that suppresses inflammatory cytokines and immune cell recruitment in the airways. Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:45.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance treatment"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00235053","phase":"PHASE4","title":"Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID","status":"COMPLETED","sponsor":"Allergy & Asthma Medical Group & Research Center","startDate":"2005-08","conditions":"Asthma, Candidiasis, Oral, Voice Disorders","enrollment":13},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT05982990","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT05085587","phase":"PHASE1","title":"Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-10-01","conditions":"Bioequivalence, Asthma","enrollment":18},{"nctId":"NCT04746040","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-01-18","conditions":"Bioequivalence, Asthma","enrollment":50},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT04790838","phase":"","title":"Pooled Analysis FP_SX_250_50","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-06-02","conditions":"Asthma","enrollment":82},{"nctId":"NCT04466176","phase":"PHASE1","title":"A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-07-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04462822","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-08-24","conditions":"Bioequivalence","enrollment":14},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT03894280","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-03-12","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT03820180","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-01-23","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT02061280","phase":"PHASE4","title":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2013-10","conditions":"Asthma","enrollment":108},{"nctId":"NCT01967173","phase":"PHASE3","title":"Best African American Response to Asthma Drugs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT00355342","phase":"PHASE4","title":"Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":186},{"nctId":"NCT00395304","phase":"PHASE3","title":"Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-03","conditions":"Asthma","enrollment":182},{"nctId":"NCT01540708","phase":"PHASE1","title":"A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Asthma","enrollment":36},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT03238482","phase":"PHASE1","title":"Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-08-16","conditions":"Asthma","enrollment":64},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT00455923","phase":"PHASE4","title":"SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-03","conditions":"Asthma","enrollment":100},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT00351143","phase":"PHASE4","title":"A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07-26","conditions":"Asthma","enrollment":274},{"nctId":"NCT01437995","phase":"PHASE4","title":"Long-acting Beta Agonist Step Down Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Asthma","enrollment":459},{"nctId":"NCT02055352","phase":"PHASE4","title":"Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":222},{"nctId":"NCT00901368","phase":"PHASE4","title":"FACTO Study (Foster® As Complete Treatment Option)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-05","conditions":"Asthmatic Patients","enrollment":431},{"nctId":"NCT00497237","phase":"PHASE3","title":"Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-04","conditions":"Asthma","enrollment":382},{"nctId":"NCT01393145","phase":"PHASE3","title":"Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD","status":"WITHDRAWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT00549146","phase":"PHASE3","title":"Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":290},{"nctId":"NCT00974246","phase":"PHASE4","title":"The Effect on Depressive Symptoms in ECF Residents With COPD","status":"COMPLETED","sponsor":"Valley Medical Research","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease, Depression","enrollment":30},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00741767","phase":"NA","title":"The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":"Chronic Obstructive Pulmonary Disease, Sleep Disorders","enrollment":""},{"nctId":"NCT01521455","phase":"PHASE1","title":"Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-02","conditions":"Asthma","enrollment":56},{"nctId":"NCT00559312","phase":"NA","title":"The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2007-12","conditions":"COPD","enrollment":18},{"nctId":"NCT00655616","phase":"NA","title":"Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2007-08","conditions":"Asthma","enrollment":64},{"nctId":"NCT00784485","phase":"PHASE4","title":"Non-invasive Measures of Effects of Xolair in Asthma","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2009-02","conditions":"Asthma","enrollment":13},{"nctId":"NCT01255579","phase":"PHASE4","title":"Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2007-07","conditions":"Bronchial Asthma","enrollment":10},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fluticasone/salmeterol DISKUS 250/50","genericName":"fluticasone/salmeterol DISKUS 250/50","companyName":"Allergy & Asthma Medical Group & Research Center","companyId":"allergy-asthma-medical-group-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate (inhaled corticosteroid) reduces airway inflammation while salmeterol (long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}